logo_new.jpg
ObsEva SA Link to Annual Report 2019
March 05, 2020 04:43 ET | ObsEva SA
  Geneva, Switzerland and Boston, MA – March 5, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
logo_new.jpg
ObsEva Announces Year End 2019 Financial Results and Business Update
March 05, 2020 01:00 ET | ObsEva SA
  Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month...
logo_new.jpg
ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
January 15, 2020 01:00 ET | ObsEva SA
  Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020Enrollment of linzagolix US and EU Phase 3...
logo_new.jpg
ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China
January 13, 2020 01:00 ET | ObsEva SA
  Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a sublicense agreement to develop and commercialize nolasiban...
logo_new.jpg
Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint
November 07, 2019 01:00 ET | ObsEva SA
   Company to Discontinue Current Nolasiban IVF Program   Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and...
logo_new.jpg
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF
October 31, 2019 02:00 ET | ObsEva SA
  FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the...
logo_new.jpg
ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
October 09, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA –October 9, 2019- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss  clinical-stage biopharmaceutical company focused on the development and commercialization of...
logo_new.jpg
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
September 03, 2019 01:00 ET | ObsEva SA
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial...
logo_new.jpg
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban
July 17, 2019 12:00 ET | ObsEva SA
                                         Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019   GENEVA, Switzerland and BOSTON, MA -  July 17, 2019 – ObsEva SA (NASDAQ:...
logo_new.jpg
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City
July 12, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – July 12, 2019– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for...